Clene Inc.


Prices are adjusted according to historical splits.

Clene Inc. Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$79.57 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Clene Inc. had its IPO on 2020-12-31 under the ticker symbol CLNN.

The company operates in the Healthcare sector and Biotechnology industry. Clene Inc. has a staff strength of 75 employees.

Stock update

Shares of Clene Inc. opened at $1.09 at the start of the last trading session i.e. 2023-06-02.

The stocks traded within a range of $0.99 - $1.09, and closed at $1.04.

This is a -0.95% slip from the previous day's closing price.

A total volume of 221,517 shares were traded at the close of the day’s session.

In the last one week, shares of Clene Inc. have increased by +8.33%.

Clene Inc.'s Key Ratios

Clene Inc. has a market cap of $79.57 million, indicating a price to book ratio of 108.1979 and a price to sales ratio of 187.0781.

In the last 12-months Clene Inc.’s revenue was $550000 with a gross profit of $447000 and an EBITDA of $-44579000. The EBITDA ratio measures Clene Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Clene Inc.’s operating margin was -8328.18% while its return on assets stood at -61.4% with a return of equity of -14530.26%.

In Q1, Clene Inc.’s quarterly earnings growth was a positive 61.4% while revenue growth was a positive 256.7%.

Clene Inc.’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-0.44 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clene Inc.’s profitability.

Clene Inc. stock is trading at a EV to sales ratio of 204.4827 and a EV to EBITDA ratio of -4.2737. Its price to sales ratio in the trailing 12-months stood at 187.0781.

Clene Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$39.89 million
Total Liabilities
$16.88 million
Operating Cash Flow
$4.72 million
Capital Expenditure
Dividend Payout Ratio

Clene Inc. ended 2023 with $39.89 million in total assets and $0 in total liabilities. Its intangible assets were valued at $39.89 million while shareholder equity stood at $-1627000.00.

Clene Inc. ended 2023 with $0 in deferred long-term liabilities, $16.88 million in other current liabilities, 8000.00 in common stock, $-204989000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $18.44 million and cash and short-term investments were $18.44 million. The company’s total short-term debt was $10,335,000 while long-term debt stood at $16.62 million.

Clene Inc.’s total current assets stands at $24.82 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $3.11 million compared to accounts payable of $608000.00 and inventory worth $88000.00.

In 2023, Clene Inc.'s operating cash flow was $4.72 million while its capital expenditure stood at $278000.

Comparatively, Clene Inc. paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Clene Inc. stock is currently trading at $1.04 per share. It touched a 52-week high of $5.13 and a 52-week low of $5.13. Analysts tracking the stock have a 12-month average target price of $8.43.

Its 50-day moving average was $1.01 and 200-day moving average was $1.47 The short ratio stood at 15.84 indicating a short percent outstanding of 0%.

Around 6420% of the company’s stock are held by insiders while 413% are held by institutions.

Frequently Asked Questions About Clene Inc.

The stock symbol (also called stock or share ticker) of Clene Inc. is CLNN

The IPO of Clene Inc. took place on 2020-12-31

Similar Industry Stocks (Biotechnology)

Last Price
Genprex Inc (GNPX)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company’s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.


6550 South Millrock Drive, Salt Lake City, UT, United States, 84121